The impact of psilocybin on visual perception and spatial orientation - neuropsychological approach

被引:0
作者
Jastrzebski, Mikolaj [1 ]
Bala, Aleksandra [1 ]
机构
[1] Wydzial Psychol UW, Katedra Neuropsychol, Pracownia Neuropsychol Poznawczej, PL-00183 Warsaw, Poland
关键词
psilocybin; psychadelic substances; visual perception; 3,4-METHYLENEDIOXYETHYLAMPHETAMINE MDE; HEALTHY-VOLUNTEERS; D-METHAMPHETAMINE; DOUBLE-BLIND; MODEL; MESCALINE; LSD;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Psilocybin is a substance of natural origin, occurring in hallucinogenic mushrooms (most common in the Psilocybe family). After its synthesis in 1958 research began on its psychoactive properties, particularly strong effects on visual perception and spatial orientation. Due to the very broad spectrum of psilocybin effects research began on the different ranges of its actions - including the effect on physiological processes (such as eye saccada movements). Neuro-imaging and neurophysiological research (positron emission tomography - PET and electroencephalography - EEG), indicate a change in the rate of metabolism of the brain and desync cerebral hemispheres. Experimental studies show the changes in visual perception and distortion from psilocybin in the handwriting style of patients examined. There are widely described subjective experiences reported by the subjects. There are also efforts to apply testing via questionnaire on people under the influence of psilocybin, in the context of the similarity of psilocybin-induced state to the initial stages of schizophrenia, as well as research aimed at creating an 'artificial' model of the disease.
引用
收藏
页码:1157 / 1167
页数:11
相关论文
共 34 条
  • [1] Aghajanian GK, 1999, NEUROPSYCHOPHARMACOL, V21, pS16
  • [2] BRAFF DL, 1980, BIOL PSYCHIAT, V15, P909
  • [3] Psilocybin impairs high-level but not low-level motion perception
    Carter, OL
    Pettigrew, JD
    Burr, DC
    Alais, D
    Hasler, F
    Vollenweider, FX
    [J]. NEUROREPORT, 2004, 15 (12) : 1947 - 1951
  • [4] Feretra G, 1965, RECENT ADV BIOL PSYC, V7, P1
  • [5] Fink M, 1978, Electroencephalogr Clin Neurophysiol Suppl, P41
  • [6] Fisher R, 1969, SWISS J PHARM, V1, P42
  • [7] Frith C, 2012, SCHIZOFRENIA
  • [8] Serotonin research: contributions to understanding psychoses
    Geyer, Mark A.
    Vollenweider, Franz X.
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (09) : 445 - 453
  • [9] Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers -: Results of an experimental double blind placebo controlled study
    Gouzoulis-Mayfrank, E
    Thelen, B
    Habermeyer, E
    Kunert, HJ
    Kovar, KA
    Lindenblatt, H
    Hermle, L
    Spitzer, M
    Sass, H
    [J]. PSYCHOPHARMACOLOGY, 1999, 142 (01) : 41 - 50
  • [10] Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers -: A double-blind, placebo-controlled PET study with [18F]FDG
    Gouzoulis-Mayfrank, E
    Schreckenberger, M
    Sabri, O
    Arning, C
    Thelen, B
    Spitzer, M
    Kovar, KA
    Hermle, L
    Büll, U
    Sass, H
    [J]. NEUROPSYCHOPHARMACOLOGY, 1999, 20 (06) : 565 - 581